Vanguard Group Inc. Has $168.10 Million Holdings in CG Oncology, Inc. (NASDAQ:CGON)

Vanguard Group Inc. grew its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 15.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,861,082 shares of the company's stock after buying an additional 779,730 shares during the period. Vanguard Group Inc. owned 7.71% of CG Oncology worth $168,096,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp lifted its holdings in CG Oncology by 73.0% during the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company's stock valued at $64,166,000 after purchasing an additional 717,722 shares during the last quarter. Geode Capital Management LLC raised its position in shares of CG Oncology by 96.2% in the third quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company's stock valued at $40,701,000 after purchasing an additional 528,749 shares during the period. Wellington Management Group LLP raised its position in shares of CG Oncology by 153.4% in the third quarter. Wellington Management Group LLP now owns 510,219 shares of the company's stock valued at $19,251,000 after purchasing an additional 308,852 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of CG Oncology by 114.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 379,664 shares of the company's stock worth $14,325,000 after buying an additional 202,262 shares during the last quarter. Finally, FMR LLC boosted its holdings in shares of CG Oncology by 83,581.6% during the 3rd quarter. FMR LLC now owns 145,606 shares of the company's stock worth $5,494,000 after buying an additional 145,432 shares during the period. 26.56% of the stock is currently owned by institutional investors.

Remove Ads

CG Oncology Price Performance

CG Oncology stock traded up $1.65 during mid-day trading on Friday, reaching $19.28. 1,714,584 shares of the company were exchanged, compared to its average volume of 706,718. The firm has a market cap of $1.47 billion, a PE ratio of -13.58 and a beta of 1.24. The company has a fifty day simple moving average of $25.19 and a 200-day simple moving average of $30.35. CG Oncology, Inc. has a 12 month low of $14.80 and a 12 month high of $46.99.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its earnings results on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.11). The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.11 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. Sell-side analysts anticipate that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Insider Buying and Selling at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the company's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $29.66, for a total transaction of $29,660.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on CGON shares. HC Wainwright restated a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a research report on Monday, March 31st. Morgan Stanley reissued an "overweight" rating and set a $55.00 price target on shares of CG Oncology in a report on Friday, March 7th. Finally, TD Cowen began coverage on CG Oncology in a research note on Tuesday, January 7th. They issued a "buy" rating for the company. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, CG Oncology presently has a consensus rating of "Buy" and a consensus target price of $63.88.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.